Whitley R J
Department of Microbiology and Medicine, University of Alabama at Birmingham 35294.
Pediatr Infect Dis J. 1994 May;13(5):432-8; discussion 438-9.
Neonatal herpes simplex virus infections cause significant morbidity and mortality among infected babies, despite the availability of antiviral therapy. These infections manifest in one of three forms: skin, eye, and mouth involvement; encephalitis; or disseminated infection. The latter two forms of disease account for more than 50% of babies with neonatal herpes and are associated with mortality and severe morbidity rates that exceed 75% in infected children. Thus future therapeutic efforts must be directed toward improved disease outcome. One such effort is the evaluation of immunoglobulin products (humanized monoclonal antibodies, human monoclonal antibodies and hyperimmune globulin) as part of a concomitant therapeutic regimen for babies with encephalitis and disseminated infection. The logic for such an approach becomes especially apparent for babies with disseminated disease because little transplacental maternal antibody is received at the time of birth. Thus concomitant administration of antiviral therapy with antibody may improve disease outcome.
尽管有抗病毒治疗方法，但新生儿单纯疱疹病毒感染仍会在受感染婴儿中导致显著的发病率和死亡率。这些感染表现为三种形式之一：皮肤、眼睛和口腔受累；脑炎；或播散性感染。后两种疾病形式占新生儿疱疹患儿的50%以上，并且与受感染儿童中超过75%的死亡率和严重发病率相关。因此，未来的治疗工作必须致力于改善疾病结局。其中一项工作是评估免疫球蛋白产品（人源化单克隆抗体、人单克隆抗体和高效价免疫球蛋白），作为脑炎和播散性感染婴儿联合治疗方案的一部分。对于患有播散性疾病的婴儿来说，这种方法的逻辑尤为明显，因为出生时从母体经胎盘获得的抗体很少。因此，抗病毒治疗与抗体的联合使用可能会改善疾病结局。
